This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Lancet (London, England), 399(10343), 2267-2279
Citation
Giudice, Linda C; As-Sanie, Sawsan; Arjona Ferreira, Juan C; Becker, Christian M; Abrao, Mauricio S; Lessey, Bruce A; Brown, Eric; Dynowski, Krzysztof; Wilk, Krzysztof; Li, Yulan; Mathur, Vandana; Warsi, Qurratul Ann; Wagman, Rachel B; Johnson, Neil P. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).. Lancet (London, England), 399(10343), 2267-2279. https://doi.org/10.1016/S0140-6736(22)00622-5